

What is Glaucoma?

What is Glaucoma?





Image Courtesy: Glaucoma Research Foundation

the most common optic neuropathy worldwide ≠ high eye pressure


Fundus Histology



~1,000,000 fibers from the Retinal Nerve Fiber Layer pass through the optic disc

Glaucoma Symptoms Appear at approx. 50% nerve fiber loss

Image Courtesy: American Academy of Ophthalmology, BLSA, 2009-2010.



Courtesy of Weng Sehu

What is the cup and disc?





Image Courtesy: Takada N, et al. 2016.

"Normal" Cup-To-Disc Ratio:

0.1-0.4

Types of Glaucoma

Aqueous Humor Dynamics




Image Courtesy: McLaren NC, et al. 2003.

Assessing the Angle





Image Courtesy: Alward WLM, Longmuir RA. 2017

Types of Glaucoma

- Closed Angle
 - Primary Angle Closure
 - Acute
 - Chronic
- Secondary Angle Closure
- Open Angle
 - Primary Open Angle Glaucoma
 - Normal Tension Glaucoma
 - Secondary Open Angle




Secondary Angle Closure

- Plateau Iris Syndrome
- Neovascular Glaucoma
- Iridocorneal Endothelial Syndrome
- Tumors
- Inflammation
- Malignant Glaucoma
- Epithelial and Fibrous Ingrowth
- Trauma
- Nanophthalmos
- Persistent Fetal Vasculature
- Drug Induced

Secondary Open Angle Glaucomas

- Pseudoexfoliation Syndrome
- Pigment Dispersion Syndrome
- Lens Induced Glaucoma
- Intraocular Tumors
- Uveitic Glaucoma
- Elevated Episcleral Venous Pressure
- Trauma and Surgery
- Schwartz Syndrome
- Medication Induced Glaucoma

What if the angle looked like this....?



If this happened acutely 360-degrees around, the patient is likely presenting as:



Acute Angle Closure Glaucoma

Image Courtesy: Alward WLM, Longmuir RA. 2017

Monitoring for Progression

Monitoring for Progression

- Optic nerve exam
- Intraocular pressure
- Visual Fields
- OCT RNFL




Consequences of Cupping

Inferior Nerve Damage

Loss of inferior temporal nerve fiber layer

24-2 Right Eye Humphrey Visual Field



SUPERIOR NASAL STEP
VISUAL FIELD DEFECT




Image Courtesy: Alward WLM, 2000.




Consequences of Cupping

Superior Nerve Damage

Loss of superior temporal nerve fiber layer

24-2 Right Eye Humphrey Visual Field



INFERIOR NASAL STEP
FIELD DEFECT




Image Courtesy: Alward WLM, 2000.




Consequences of Cupping

Arcuate Nerve Damage

Loss of Superior Arcuate nerve fiber layer

24-2 Right Eye Humphrey Visual Field



INFERIOR ARCULATE VISUAL
FIELD DEFECT




Image Courtesy: Alward WLM, 2000.




Consequences of Cupping

Hemi-Nerve Damage

Loss of Inferior Hemi-field Nerve Fiber Layer

24-2 Right Eye Humphrey Visual Field



SUPERIOR ALTITUDINAL
VISUAL FIELD DEFECT





Image Courtesy: Alward WLM, 2000.




Staging Disease




Mild

1. Glaucomatous Nerve
2. No visual field changes
- OR
3. Changes on SWAP or Frequency-Doubling Visual Field Only



Moderate

1. Glaucomatous Nerve
2. VF change 1 Hemi-field only
3. VF change not within 5-deg of fixation



Severe



1. Glaucomatous Nerve
2. VF change Both Hemi-fields and/or
3. VF change within 5-deg of fixation

PROGRESSION (TREATMENT REFRACTORY, MUST ESCALATE)
REFER BACK TO OPHTHALMOLOGIST



Image Courtesy: Mattox C, AAO 2014.

OCT RNFL



Staging Disease – What if IOP, Cup-to-disc, and VF stable, but nerve now appears:





Image Courtesy: EyeRounds, 2014

DISEASE IS STILL PROGRESSING. MUST ESCALATE TREATMENT.

Up and Coming - OCT Angiography




Treatment

Treatment

- Medical
- Lasers
- Surgical

Medical Management




CASEY EYE
Institute

Up and Coming



CASEY EYE
Institute

Lasers



CASEY EYE
Institute

When to Refer for Iridotomy

Acute Angle Closure Glaucoma – If there is adequate corneal view, consider iridotomy placement

Narrow Angles/Chronic Angle Closure – Prophylactic iridotomy if:

- Angle occludable (< 180-deg trabecular meshwork on Gonioscopy)




Image Courtesy: Vera V, et al. 2014.

CASEY EYE
Institute

Surgery - When Medicine is Not Enough

Trabecular Meshwork/Schlemm's Canal Remodeling:

- Goniotomy
- Trabeculotomy
- Laser Trabeculoplasty
- Canaloplasty

Filtration Surgery

- Trabeculectomy




Image Courtesy: New
Glaucoma Treatments, San
Marino Eye, 2018.

Tube Shunt

- Baerveldt Shunt
- Ahmed Valve





Image Courtesy: New World
Medical, Rancho Cucamonga, CA.

Cyclophotocoagulation

CASEY EYE
Institute

Up and Coming - MIGS



MIGS.org

CASEY EYE
Institute

Parting Thoughts...

- Glaucoma is usually a slow, but progressive disease
- An important modifiable risk factor is IOP
- Serial exams, visual fields, and nerve fiber analysis are critical to monitoring progression
- Any progression requires medical or surgical treatment



References

1. Muth DR, Hirneß CW. Structure-Function Relationship Between Bruch's Membrane Opening-Based Optic Nerve Head Parameters and Visual Field Defects in Glaucoma. *IOVS*. 56(5): 3320-3328. (2015).
2. Vajaranant TS, WU S, Torres M, Varma R. The Changing Face of Primary Open-Angle Glaucoma in the United States: Demographic and Geographic Changes From 2011 to 2050. *Am J Ophthalmol*. 154:303-312. (2012).
3. Takada N, Omodaka K, Kikawa T, Takagi A, et al. OCT-Based Quantification and Classification of Optic Disc Structure in Glaucoma Patients. *PLOS One*. 11(8): e0160226. (2016).
4. Burgoyne C. The morphological difference between glaucoma and other optic neuropathies. *J Neuroophthalmol*. 35: 58-521. (2015).
5. Alward WLM. Glaucoma: the requisites in ophthalmology. Krachmer JH (Ed.). St. Louis: Mosby, 2000.
6. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol*. 120:701-713. (2002).
7. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. *Pharmacogenomics J*. 3:197-201. (2003).



References

8. Pollack IP, Wilensky J. Angle Closure Glaucoma. In: *Glaucoma: Science and Practice*. Eds. Morrison JC, Pollack IP. Thieme: New York, NY. (2003).
9. Mansouri M, Ramezani F, Moghimi S, Tabatabaie A, et al. Anterior Segment Optical Coherence Tomography Parameters in Phacomorphic Angle Closure and Mature Cataracts. *IOVS*. 55:7403-7409. (2014).
10. Sun X, Dai Y, Chen Y, Yu D-Y, et al. Primary Angle Closure Glaucoma: What we know and what we don't know. *Progress in Retinal and Eye Research*. 57:26-45. (2017).
11. Vera V, Naqi A, Belovay GW, Varma DK, Ahmed IK. Dysphotopsia following Temporal versus Superior Laser Peripheral Iridotomy: a Prospective Randomized Paired Eye Trial. *American Journal of Ophthalmology*. 157(5):929-935. (2014).
12. Collaborative Normal-Tension Study Group. Comparison of Glaucomatous Progression Between Untreated Patients with Normal-Tension Glaucoma and Patients with Therapeutically Reduced Intraocular Pressures. *American Journal of Ophthalmology*. 126(4): 487-497. (1998).



Overview

Extent of Primary Open Angle Glaucoma

Understanding Cup-to-Disc Assessment

Types of Visual Field Defects Common to Glaucomatous Injury


Risk Factors for Progression and Pressure Management

Aqueous Humour and the Anterior Chamber Angle

Angle Closure



What about Oregon?



Normal Tension Glaucoma

Patients with:

1. Glaucomatous Appearing Nerves
2. Visual Field Defects
3. Intraocular Pressure < 21

Comparison of Glaucomatous Progression Between Untreated Patients With Normal-Tension Glaucoma and Patients With Therapeutically Reduced Intraocular Pressures

COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP*

1. IOP IS A FACTOR IN THE PATHOGENESIS OF NORMAL TENSION GLAUCOMA
2. LOWERING IOP BY 30% IS BENEFICIAL
3. RATE OF PROGRESSION ACCELERATES WITH FEMALE GENDER, H/O MIGRAINES, and DISC HEMORRHAGES



Risk Factors for Nerve Damage from Primary Open Angle Glaucoma

CLINICAL SCIENCES

The Ocular Hypertension Treatment Study

A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma

Michael A. Kass, MD; Dale K. Heuer, MD; Eve J. Higginbotham, MD; Chris A. Johnson, PhD; John L. Keltner, MD; J. Philip Miller, AB; Richard K. Parrish II, MD; M. Roy Wilson, MD; Mae O. Gordon, PhD; for the Ocular Hypertension Treatment Study Group

- Baseline Intraocular Pressure - Modifiable
- Age
- Cup-to-disc ratio
- Central Corneal Thickness (CCT, < 555 microns)

Other Risk Factors from Other Studies

Race
Family History
Diabetes
Hypertension
Myopia
Migraines




A Little More on Intraocular Pressure (IOP)

20% reduction in baseline IOP →

Risk of Visual Field Loss without Medication
9.5%

Risk of Visual Field Loss with Medication
4.4%



Factors Favoring Angle Closure

Lens-Induced or Phacomorphic Glaucoma




Image Courtesy: Mansouri M, et al. 2014.




Image Courtesy: Sun X, et al. 2017.

- Narrow Angle
- Shallow Anterior Chamber Depth
- Small Corneal Diameter
- Increased Lens Thickness
- Physiologic Mydriasis (natural large pupils)
- Pharmacologic Mydriasis (medical dilation)
- Multiple Systemic Medications

